INOVIO (NASDAQ:INO) announced on November 18, 2026 that it has submitted a Conditional Marketing Authorization application to the European Medicines Agency for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) as a treatment for adults with Recurrent Respiratory Papillomatosis.
Key Highlights
- EMA submission filed: INOVIO submitted a Conditional Marketing Authorization application to the European Medicines Agency for VOCERYQ as a treatment for adults with RRP.
- FDA accelerated approval: VOCERYQ received FDA accelerated approval on October 30, 2026 for adults with RRP to reduce the frequency of surgery.
- U.S. commercial timeline: INOVIO expects to make VOCERYQ available to order and ship in the U.S. in approximately 60 days from the date of FDA approval, with full commercial launch expected in the first quarter of 2027.
- Orphan Drug and ATMP designations: The European Commission granted Orphan Drug designation to INO-3107 for RRP in 2023, and INO-3107 also received an Advanced Therapy Medicinal Product Certification from the EMA's Committee for Advanced Therapies.
- CE-marked device: The CELLECTRA delivery device has a CE-mark in the EU, allowing INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.
- Estimated U.S. patient population: Based on ongoing analysis of claims data, INOVIO believes there is a prevalent population of at least 25,000 patients with RRP in the United States.
INOVIO Seeks European Approval for VOCERYQ After U.S. FDA Clearance
According to the filing, INOVIO submitted its Conditional Marketing Authorization application to the European Medicines Agency for VOCERYQ, described as the first FDA-approved plasmid DNA-based immunotherapy. The application covers VOCERYQ as a treatment for adults with Recurrent Respiratory Papillomatosis, a rare disease caused primarily by HPV-6 and/or HPV-11 that is characterized by wart-like growths in the respiratory tract. The company disclosed that Europe currently has no approved non-surgical treatment options that target the root cause of RRP.
The filing states that the CMA application is supported by preclinical, clinical, and manufacturing data, including results from clinical studies published in 2025 in Nature Communications and The Laryngoscope, as well as an additional analysis published in October 2026 in The Laryngoscope under the title "DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP." The company also noted that it submitted the application using guidance from pre-submission meetings with the EMA and the Rapporteurs.
Regarding VOCERYQ's U.S. status, the filing notes that the FDA's accelerated approval "may be contingent on verification and description of clinical benefit in a confirmatory study(ies)." The filing describes VOCERYQ as a plasmid DNA-based immunotherapy administered using the CELLECTRA 5PSP delivery device, with a 9-week dosing regimen following a standard-of-care surgical debulking. The FDA previously granted VOCERYQ both Orphan Drug and Breakthrough Therapy designations, according to the filing. The press release contains forward-looking statements subject to the company's cautionary language under the Private Securities Litigation Reform Act of 1995.
What Was Disclosed
INOVIO disclosed the submission of a Conditional Marketing Authorization application to the EMA for VOCERYQ for adult RRP patients, building on the drug's October 30, 2026 FDA accelerated approval, and provided U.S. commercial launch timing expectations.





Please wait processing your request...